Abbott Laboratories (ABT) reported third quarter earnings of 92 cents per share, 2 cents above the Zacks Consensus Estimate of 90 cents.
Results were above the company’s guidance of 88 – 90 cents. Earnings increased 16.5% from the year-ago period. Total revenues grew 3.5% to $7,761 million. Revenues were negatively impacted by 4.9% due to foreign exchange (Fx) headwinds.
Sales in the Pharmaceutical division totaled $4,055 million, down 1.6% and negatively impacted by about 5.5% due to Fx. Strong Humira and lipid franchise sales were offset by weak performance of Depakote, which is facing intense generic competition.
The lipid franchise posted sales of $545 million. The recent launch of TriLipix, which will be co-promoted with AstraZeneca (AZN), should help drive lipid franchise sales.
Meanwhile, we were pleased to see that Humira continued to perform well in both U.S. and international markets — we expect the product to play an important role in Abbott’s growth story. Including the negative impact of Fx, Abbott expects Humira sales growth of 18-20%, up from the earlier guidance. We believe the product is gaining share from Amgen/Wyeth’s (AMGN/WYE) Enbrel and Johnson & Johnson’s (JNJ) Remicade. Sales increased to $1.491 billion.
The Nutritional business posted sales of $1,386 million in the quarter, up 9.8%. The segment is enjoying strong growth in key emerging markets, including Latin America and Asia. Abbott Diagnostics posted sales of $909 million in the quarter, representing a decrease of 0.3%. However, excluding the Fx impact of 6.1%, sales would have been up 5.8%.
The Vascular division continued to perform well, with sales increasing 4.7% to $666 million. XIENCE V continues to gain market share. The company stated that the XIENCE platform, consisting of XIENCE V and Promus, accounts for more than half of the U.S. market. Meanwhile, other division sales totaled $745 million, representing growth of 31.4%.
Based on the better-than-expected results, management increased earnings guidance for 2009. The company expects earnings in the range of $3.70 – $3.72 per share, up from the previous guidance of $3.65 – $3.70.
Although economic weakness and Fx headwinds have slowed down top-line growth, we believe Abbott is weathering the storm relatively well. Abbott’s strong business segments, contributions from recent acquisitions and impressive late-stage pipeline should help fortify long-term earnings growth. Humira will continue to be a huge growth-driver going forward. We have a Neutral rating on the stock.
Read the full analyst report on “ABT”
Read the full analyst report on “AMGN”
Read the full analyst report on “WYE”
Read the full analyst report on “AZN”
Read the full analyst report on “JNJ”
Zacks Investment Research
